ArticleNature biomedical engineering2024
Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression.
Article in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Biomimetic zona pellucida-encapsulated islets for sustained glycaemic control in immunocompetent mice.Nature biomedical engineering · 2026Article
- A Self-Oxygenating Wound-Adaptive Stem Cell Encapsulation Platform for Chronic Wound Repair.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Electron paramagnetic resonance (EPR) meets drug delivery and biomaterials: a magnetic love story.Drug delivery and translational research · 2026Review
- Prevascularized grafts with spatially organized MSC spheroids to accelerate therapeutic angiogenesis in ischemic disease.Angiogenesis · 2026Article
- Miniaturized subcutaneous cellular implants for sustained therapeutic protein delivery in resource-limited settings.bioRxiv : the preprint server for biology · 2026Article
- Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.Biomedical microdevices · 2026Article
- Engineering the oxygen microenvironment for pancreatic islet transplants.NPJ Regenerative medicine · 2026Review
- Beta-cell replacement for type 1 diabetes: integrating cell products, engraftment and immune protection.Frontiers in endocrinology · 2026Review
- Oxygen dynamics and delivery strategies to enhance beta cell replacement therapy.American journal of physiology. Cell physiology · 2025Review
- Composite spin probes with adjustable oxygen sensitivity for pulse electron paramagnetic resonance imaging.Magnetic resonance in medicine · 2025Article
- Bioprinted platform for parallelized screening of engineered microtissues in vivo.Cell stem cell · 2025Article
- In Vivo Mouse Abdominal Oxygen Imaging And Assessment of Subcutaneously Implanted Beta Cell Replacement Devices.Molecular imaging and biology · 2025Article
- Advancements and Challenges in Immune Protection Strategies for Islet Transplantation.Journal of diabetes · 2025Review
- The role of endothelial cells in pancreatic islet development, transplantation and culture.Frontiers in cell and developmental biology · 2025Review
- Materials approaches for next-generation encapsulated cell therapies.MRS communications · 2025Review
- High-Efficiency, Prevascularization-Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Islet cell spheroids produced by a thermally sensitive scaffold: a new diabetes treatment.Journal of nanobiotechnology · 2024Article
- Mesenchymal stem cell conditioned medium improves hypoxic injury to protect islet graft function.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Recent Advances in Alginate-Based Hydrogels for Cell Transplantation Applications.Pharmaceutics · 2024Review
- Pancreatic islet transplantation: current advances and challenges.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular therapies for type-1 diabetes can leverage cell encapsulation to dispense with immunosuppression. However, encapsulated islet cells do not survive long, particularly when implanted in poorly vascularized subcutaneous sites. Here we show that the induction of neovascularization via temporary controlled inflammation through the implantation of a nylon catheter can be used to create a subcutaneous cavity that supports the transplantation and optimal function of a geometrically matching islet-encapsulation device consisting of a twisted nylon surgical thread coated with an islet-seeded alginate hydrogel. The neovascularized cavity led to the sustained reversal of diabetes, as we show in immunocompetent syngeneic, allogeneic and xenogeneic mouse models of diabetes, owing to increased oxygenation, physiological glucose responsiveness and islet survival, as indicated by a computational model of mass transport. The cavity also allowed for the in situ replacement of impaired devices, with prompt return to normoglycemia. Controlled inflammation-induced neovascularization is a scalable approach, as we show with a minipig model, and may facilitate the clinical translation of immunosuppression-free subcutaneous islet transplantation.
Indexed as
Identifiers
38052996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.